Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients-Reference-Cited by-同舟云学术

Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients

Published:2020-10 Issue: Volume:151 Page:26-32
ISSN:0167-8140
Container-title:Radiotherapy and Oncology
language:en
Short-container-title:Radiotherapy and Oncology

Author:

Levin-Epstein Rebecca,Cook Ryan R.,Wong J. Karen,Stock Richard G.,Jeffrey Demanes D.,Collins Sean P.,Aghdam Nima^ORCID,Suy Simeng,Mantz Constantine,Katz Alan J.,Nickols Nicholas G.,Miszczyk Leszek,Napieralska Aleksandra,Namysl-Kaletka Agnieszka,Prionas Nicholas D.,Bagshaw Hilary^ORCID,Buyyounouski Mark K.,Cao Minsong,Mahal Brandon A.,Shabsovich David^ORCID,Dang Audrey,Yuan Ye^ORCID,Rettig Matthew B.,Chang Albert J.^ORCID,Jackson William C.,Spratt Daniel E.,Lehrer Eric J.^ORCID,Zaorsky Nicholas G.^ORCID,Kupelian Patrick A.,Steinberg Michael L.,Horwitz Eric M.,Jiang Naomi Y.,Kishan Amar U.

Funder

Prostate Cancer Foundation

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,Hematology

Reference22 articles.

1. Mohler JL, Hurwitz M, Richey S. Prostate Cancer version 1.2020. NCCN Guidelines. Published online 2020.

2. Population-based study of biochemical and survival outcomes after permanent 125I brachytherapy for low- and intermediate-risk prostate cancer;Morris;Urology,2009

3. High-dose-rate brachytherapy monotherapy without androgen deprivation therapy for intermediate-risk prostate cancer;Patel;Brachytherapy,2017

4. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer;Kishan;JAMA Netw Open,2019

5. Lazarev S, Thompson MR, Stone NN, Stock RG. Low-dose-rate brachytherapy for prostate cancer: outcomes at >10 years of follow-up. BJU Int 2018;121:781–790. doi:10.1111/bju.14122

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Simultaneous Focal Boost With Stereotactic Radiation Therapy for Localized Intermediate- to High-Risk Prostate Cancer: Primary Outcomes of the SPARC Phase 2 Trial;International Journal of Radiation Oncology*Biology*Physics;2024-09

2. Prostate high dose-rate brachytherapy as monotherapy for low and intermediate-risk prostate cancer: Efficacy results from a randomized phase II clinical trial of one fraction of 19 Gy or two fractions of 13.5 Gy: A 9-year update;Radiotherapy and Oncology;2024-09

3. Global research status and hotspots of radiotherapy for prostate cancer: a bibliometric analysis based on Web of Science from 2010-2022;Frontiers in Oncology;2023-08-11

4. Genitourinary Sites;Handbook of Evidence-Based Stereotactic Radiosurgery and Stereotactic Body Radiotherapy;2023

5. Stereotactic Radiation Therapy versus Brachytherapy: Relative Strengths of Two Highly Efficient Options for the Treatment of Localized Prostate Cancer;Cancers;2022-04-29